750.07 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/21/2024 2:04:10 PM)
Exchange open, closes in 1 hour 55 minutes
0.53 USD (0.53%)
-3.24 USD (-3.24%)
-19.73 USD (-19.73%)
-6.96 USD (-6.96%)
25.63 USD (25.63%)
559.47 USD (559.47%)
1,053.51 USD (1,053.51%)
1,343.50 USD (1,343.50%)

About Eli Lilly &

Market Capitalization 715.22B

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Headquarters (address)

Lilly Corporate Center

Indianapolis 46285 IN

United States

Phone317 276 2000
Websitehttps://www.lilly.com
Employees43,000
SectorHealthcare
IndustryDrug Manufacturers General
TickerLLY
ExchangeNew York Stock Exchange
CurrencyUSD
52 week range561.65 - 972.53
Market Capitalization715.22B
Dividend yield forward0.690 %
Dividend yield forward United States (ID:6, base:1864) 4.22 %
P/E trailing81.27
P/E forward33.25
Price/Sale17.50
Price/Book47.61
Beta0.430
EPS9.27
EPS United States (ID:6, base:3391) 24.31

Forward Annual Dividend Yield

Forward Annual Dividend Yield: Eli Lilly & has raised their dividend 0.690 years in a row. This is below the 41113.877400 year average in the 'Drug Manufacturers General' industry

Compound Average Growth Rate 3 Years

Compound Average Growth Rate 3 Years: Eli Lilly & has raised their dividend 4.63 years in a row. This is below the 24.014500 year average in the 'Drug Manufacturers General' industry

Compound Average Growth Rate 5 Years

Compound Average Growth Rate 5 Years: Eli Lilly & has raised their dividend 8.54 years in a row. This is below the 12.586200 year average in the 'Drug Manufacturers General' industry

Compound Average Growth Rate 10 Years

Compound Average Growth Rate 10 Years: Eli Lilly & has raised their dividend 5.63 years in a row. This is below the 10.156100 year average in the 'Drug Manufacturers General' industry

Payout Ratio

Payout Ratio: Eli Lilly & has raised their dividend 54.20 years in a row. This is below the 146.967900 year average in the 'Drug Manufacturers General' industry

Forward Annual Dividend Yield

Forward Annual Dividend Yield: Eli Lilly & has raised their dividend 0.690 years in a row. This is below the 41113.877400 year average in the 'Drug Manufacturers General' industry

Compound Average Growth Rate 3 Years

Compound Average Growth Rate 3 Years: Eli Lilly & has raised their dividend 4.63 years in a row. This is below the 24.014500 year average in the 'Drug Manufacturers General' industry

Compound Average Growth Rate 5 Years

Compound Average Growth Rate 5 Years: Eli Lilly & has raised their dividend 8.54 years in a row. This is below the 12.586200 year average in the 'Drug Manufacturers General' industry

Compound Average Growth Rate 10 Years

Compound Average Growth Rate 10 Years: Eli Lilly & has raised their dividend 5.63 years in a row. This is below the 10.156100 year average in the 'Drug Manufacturers General' industry

Payout Ratio

Payout Ratio: Eli Lilly & has raised their dividend 54.20 years in a row. This is below the 146.967900 year average in the 'Drug Manufacturers General' industry

CleverShares.com|
2024 ©

1.0.9089.36765